Bradford Zakes recently helped combine the Seattle-area biotech company he led, Cerevast Medical, with two startups to create a new company. Now he’s poised to take Longevity Biomedical public as its president and CEO, via a merger with a shell company.
The merger is expected to raise at least $30 million for Bothell, Wash.-based Longevity. The deal, which merges Longevity with a SPAC (special purpose acquisition company), is expected to close in the second quarter of this year.
